ArticleInternational journal of cancer2026
Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) patients with EGFR mutations usually receive continuous treatment with tyrosine kinase inhibitors (TKIs) until disease progression. We evaluated whether surgical excision of residual tumor masses offers a survival advantage when performed before progression on TKI therapy. We conducted a retrospective analysis of 230 patients with locally advanced or metastatic EGFR-mutated NSCLC who were treated with first-line EGFR TKI. Among these subjects, surgical intervention appeared technically feasible in 57 patients, 41 of whom underwent cytoreductive surgery while 16 were not operated for various reasons. Both surgically treated and nonsurgically treated patients received TKI until disease progression. The median duration of TKI treatment before surgery was 7.3 months. There was no perioperative mortality, while 8/41 (19.5%) patients experienced surgery-related complications. The median progression-free survival (PFS) and overall survival (OS) in the surgically treated group were 28.4 months and 46.9 months, respectively. These outcomes were significantly better than in patients with potentially resectable disease who did not undergo surgery (PFS: 15.4 months, p = 0.010; OS: 26.5 months, p = 0.015), or in subjects not amenable to cytoreduction (PFS: 19.0 months, p = 0.006; OS: 31.7 months, p = 0.001). Mutation analysis of residual tumor tissues revealed emerging TKI-resistant clones in 4 of 21 investigated patients. At the time of data cut-off, 12/41 (29%) surgically treated patients remained disease-free. In conclusion, surgical removal of residual tumor masses in EGFR-mutated NSCLC during response to TKI may confer a survival advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.